Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France-Reference-Cited by-同舟云学术

Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France

Published:2022-05-30 Issue:1 Volume:25 Page:691-699
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Grumberg Valentine¹²^ORCID,Chouaïd Christos³⁴^ORCID,Cotté François-Emery¹^ORCID,Jouaneton Baptiste⁵^ORCID,Jolivel Ronan⁵^ORCID,Gaudin Anne-Françoise¹^ORCID,Reynaud Dorothée¹^ORCID,Assié Jean-Baptiste³⁶^ORCID,Borget Isabelle²⁷^ORCID

Affiliation:

1. Bristol Myers Squibb France, Rueil-Malmaison, France

2. Oncostat, CESP, INSERM U1018, Paris-Saclay University, “Ligue Contre le Cancer” labeled team, Villejuif, France

3. Department of Chest Medicine, Créteil University Hospital, Créteil, France

4. INSERM U955, UPEC, IMRB, Créteil, France

5. HEVA, Lyon, France

6. INSERM U1138 Centre de Recherche des Cordeliers (CRC), Paris, France

7. Biostatistics and Epidemiology Office, Direction of Clinical Research, Gustave Roussy, Paris-Saclay University, Villejuif, France

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2079291

Reference25 articles.

1. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018

2. Haute Autorité de Santé. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2013-10/guide_k_bronchopulmonaires_finalweb__091013.pdf.

3. Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study)

4. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

5. Caisse Nationale d’Assurance Maladie. Available from: https://assurance-maladie.ameli.fr/sites/default/files/rapport-charges-et-produits-2020.pdf.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does pathologic type shape the hospitalization costs of advanced non- small cell lung cancer patients? A multicenter real-world data study;2024-01-05

2. Characteristics, management, and healthcare resources of patients with advanced non–small-cell lung cancer surviving 5 years after nivolumab treatment initiation: A national database analysis;Respiratory Medicine and Research;2023-11